Eli Lilly Submits New Type 2 Diabetes Drug for FDA Review

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Eli Lilly (NYSE: LLY  ) and research partner Boehringer Ingelheim announced today that they have submitted a New Drug Application to the U.S. Food and Drug Administration to treat Type 2 diabetes.

The sodium glucose co-transporter-2 inhibitor empagliflozin is part of a larger class of drugs being tested for their ability to reduce blood glucose levels in Type 2 diabetic adults by blocking the kidneys from reabsorbing high-glucose urine.

"We are excited to have submitted an application for a potential new treatment option that may help patients better manage their Type 2 diabetes mellitus," said Dr. Christophe Arbet-Engels, Boehringer Ingelheim's VP of metabolic-clinical development and affairs. "Type 2 diabetes mellitus is a critical health issue facing the world today, and through the Boehringer Ingelheim and Lilly Diabetes Alliance, we are committed to developing new treatments to address patients with this disease."

The class of drugs is currently part of 12 multinational clinical trials and is in phase 3 clinical trials with the FDA. Looking ahead, Eli Lilly and Boehringer Ingelheim expect to release results of these studies throughout 2013 and 2014.

According to Eli Lilly, Type 2 diabetes accounts for 90% of all diabetes cases worldwide,and resulted in approximately $245 billion of medical costs and lost productivity in 2012.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 26, 2013, at 12:48 AM, DannyHaszard wrote:

    Zyprexa Diabetes connection conflict of interest.

    Eli Lilly paid billions in fines for the scam.

    Thousands got diabetes as Zyprexa side effect and have to take Lilly insulin to treat the diabetes that was caused by their Zyprexa.

    Eli Lilly Zyprexa can ruin your Pancreas and make you a type 2 diabetic in just a few months of use.I took it 1996-2000 and now am a diabetic for it.

    'Atypical' antipsychotic Zyprexa is the worst offender of them all.Google Haszard Zyprexa got a page up.

    -Daniel Haszard

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2330719, ~/Articles/ArticleHandler.aspx, 9/25/2016 8:24:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:01 PM
LLY $81.16 Down -0.13 -0.16%
Eli Lilly and Co. CAPS Rating: ***